Niemann Pick C disease is a rare, fatal lipid-storage disorder with no known cure. 95% of patients carry mutations in *NPC1* (Niemann-Pick disease, type C1), which encodes a protein involved in the intra-cellular trafficking of low-density lipoprotein (LDL)-derived cholesterol and plasma-derived glycolipids. Studies of mammalian models have shed light on pathological mechanisms caused by the mutation; now, Schwend et al. approach the issue from a developmental angle by identifying and studying the role of *npc1* in the zebrafish embryo. They find that *npc1* morphants display numerous abnormalities, including cholesterol mislocalisation, cell-movement defects and, at later stages of embryogenesis, cell death. Complementation of *npc1* morphants with mouse *Npc1* rescues the defect, indicating a high degree of gene homology between fish and mammals. Treatment of *npc1* morphants with steroids also rescues the defects, suggesting that reduced steroidogenesis is responsible for pathology caused by *npc1* loss of function. This study provides new clues for how to treat Niemann Pick C disease in humans, and suggests that the zebrafish embryo is a valid model to screen for novel therapies.
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